Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New contraceptive device under attack:

This article was originally published in Clinica

Executive Summary

Unipath has admitted that around 450 women have become pregnant while using the company's Persona contraceptive device, hailed as a rival to the pill at its launch last September 30th. The device, which has been bought by more than 100,000 women from Boots chemists, measures hormone levels in urine to establish when a woman is fertile (see Clinica No 726, p 17). Unipath has recently reduced its claimed success rate for Persona from 95% to 94%, it told the BBC's Watchdog Healthcare programme. Clinica estimates the failure rate at 1.8%.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT084413

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel